This HTML5 document contains 38 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n19http://linked.opendata.cz/resource/AHFS/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00055/identifier/drugbank/
n14http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00055/identifier/national-drug-code-directory/
n13http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n15http://www.rxlist.com/cgi/generic/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00055/identifier/genbank/
n11http://linked.opendata.cz/resource/drugbank/patent/
n23http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00055/identifier/uniprotkb/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n22http://linked.opendata.cz/resource/drugbank/drug/DB00055/identifier/wikipedia/
n10http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n8http://www.drugs.com/cdi/
n6http://linked.opendata.cz/resource/drugbank/drug/DB00055/identifier/pharmgkb/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n18http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00055
rdf:type
n3:Drug
n3:description
Drotrecogin alfa is activated human protein C that is synthesized by recombinant DNA technology. It is a glycoprotein of approximately 55 kilodalton molecular weight, consisting of a heavy chain and a light chain linked by a disulfide bond. Drotrecogin alfa was withdrawn from the market after a major study indicated that it was not effective in improving outcomes in patients with sepsis.
n3:group
withdrawn approved investigational
n3:halfLife
5.5 hours (mammalian reticulocytes, in vitro).
n3:indication
For reduction of mortality in patients with severe sepsis.
owl:sameAs
n13:DB00055 n23:DB00055
dcterms:title
Drotrecogin alfa
adms:identifier
n6:PA131548935 n16:P04070 n17:DB00055 n20:0002-7559-01 n21:M11228 n22:Drotrecogin_alfa
n3:mechanismOfAction
Activated protein C combines with protein S on platelet surfaces and then degrades factor Va and factor VIIIa, thereby reducing blood coagulability.
n3:packager
n14:271B426A-363D-11E5-9242-09173F13E4C5 n14:271B4269-363D-11E5-9242-09173F13E4C5
n3:patent
n11:2139468 n11:2036894
n3:synonym
Anticoagulant protein C Blood coagulation factor XIV Autoprothrombin IIA Vitamin K-dependent protein C precursor
n18:hasAHFSCode
n19:20-12-20
foaf:page
n8:drotrecogin-alfa.html n15:drotrecogin.htm
n3:Molecular-Formula
n4:271B4270-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B426F-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
60202-16-6
n3:category
n3:clearance
* 40 L/hr [severe sepsis adults] * 30 +/- 8 L/hr [patients without sepsis undergoing hemodialysis] * 28 +/- 9 L/hr [heathy]
n3:containedIn
n10:271B426C-363D-11E5-9242-09173F13E4C5 n10:271B426B-363D-11E5-9242-09173F13E4C5
n3:Hydrophobicity
n4:271B426D-363D-11E5-9242-09173F13E4C5
n3:Isoelectric-Point
n4:271B426E-363D-11E5-9242-09173F13E4C5